Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Genomics: Clinical Implementation » Bio-Techne Bets Clinical Utility Study Data Will Sway Payors to Cover Prostate Cancer Risk Test

Bio-Techne Bets Clinical Utility Study Data Will Sway Payors to Cover Prostate Cancer Risk Test

May 20, 2020
|
John Gilmore
Premium

This story has been updated to include responses from Bio-Techne regarding commentary on the paper from unaffiliated academic sources.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Lots of Voided Tests

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Score Disparities Found

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

Maybe an RNA-DNA World

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

Nature Papers Describe Sequencing of Sperm Genomes, Approach to Detect Residual Cancer, More

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

What's Popular?

In Molecular Diagnostics

  1. Tumor Mutational Burden in Blood May Predict Immunotherapy Response in Head, Neck Cancer

  2. FDA Issues Emergency Use Authorizations for Gravity Diagnostics, Aspirus, CSI Coronavirus Tests

  3. Guardant Health Prices $315M Public Offering

  4. Ravgen Sues Natera Over Cell-Free DNA Genetic Testing Patents

  5. OpGen Expands Partnership With New York State Department of Health to Detect AMR Infections

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.